Reply
Manuel Mendizabal, Nicolás Ducasa, Paula Benencio, Mirna Biglione, Ezequiel Mauro – 9 October 2022
Manuel Mendizabal, Nicolás Ducasa, Paula Benencio, Mirna Biglione, Ezequiel Mauro – 9 October 2022
Brianna C. M. Wellen, Henry C. Lin, Jacklyn E. Stellway – 9 October 2022
Alexis Gumm, Antonio Perez‐Atayde, Andrew Wehrman – 9 October 2022
Jessica Howell, Huy Van, Minh Pham, Rohit Sawhney, Fan Li, Purnima Bhat, John Lubel, William Kemp, Stephen Bloom, Avik Majumdar, Geoff McCaughan, Samuel Hall, Timothy Spelman, Joseph S. Doyle, Margaret Hellard, Kumar Visvanathan, Alexander J. Thompson, Heidi E. Drummer, David Anderson – 9 October 2022
Alexis Gumm, Antonio Perez‐Atayde, Andrew Wehrman – 9 October 2022
Jessica Howell, Huy Van, Minh Pham, Rohit Sawhney, Fan Li, Purnima Bhat, John Lubel, William Kemp, Stephen Bloom, Avik Majumdar, Geoff McCaughan, Samuel Hall, Timothy Spelman, Joseph S. Doyle, Margaret Hellard, Kumar Visvanathan, Alexander J. Thompson, Heidi E. Drummer, David Anderson – 9 October 2022
Brianna C. M. Wellen, Henry C. Lin, Jacklyn E. Stellway – 9 October 2022
Akiko Eguchi, Motoh Iwasa, Ryosuke Sugimoto, Mina Tempaku, Kyoko Yoshikawa, Naohiko Yoshizawa, Davide Povero, Kazushi Sugimoto, Hiroshi Hasegawa, Yoshiyuki Takei, Hayato Nakagawa – 4 October 2022 – Complement complex 1 subunit q (C1q) has multiple functions, including cell migration, in addition to its traditional complement‐activating effect. Research shows C1q is a ligand for frizzled receptors (FZDs).
Xiaolin Wang, Seung‐Jin Kim, Yukun Guan, Richard Parker, Robim M. Rodrigues, Dechun Feng, Shelly C. Lu, Bin Gao – 4 October 2022 – Adipose tissue dysfunction is closely associated with the development and progression of nonalcoholic fatty liver disease (NAFLD). Recent studies have implied an important role of prohibitin‐1 (PHB1) in adipose tissue function. In the current study, we aimed to explore the function of adipocyte PHB1 in the development and progression of NAFLD.
Jie Jiang, Yuandi Ma, Yameng Liu, Dasheng Lu, Xiaoxia Gao, Kristopher W. Krausz, Dhimant Desai, Shantu G. Amin, Andrew D. Patterson, Frank J. Gonzalez, Cen Xie – 4 October 2022 – Nonalcoholic steatohepatitis (NASH) is a rapidly developing pathology around the world, with limited treatment options available. Some farnesoid X receptor (FXR) agonists have been applied in clinical trials for NASH, but side effects such as pruritus and low‐density lipoprotein elevation have been reported. Intestinal FXR is recognized as a promising therapeutic target for metabolic diseases.